ABSTRACT
INTRODUCTION AND OBJECTIVES: This article presents the annual activity report of the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC) for the year 2022. METHODS: All Spanish centers with catheterization laboratories were invited to participate. Data were collected online and were analyzed by an external company in collaboration with the members of the board of the ACI-SEC. RESULTS: A total of 111 centers participated. The number of diagnostic studies increased by 4.8% compared with 2021, while that of percutaneous coronary interventions (PCI) remained stable. PCIs on the left main coronary artery increased by 22%. The radial approach continued to be preferred for PCI (94.9%). There was an upsurge in the use of drug-eluting balloons, as well as in intracoronary imaging techniques, which were used in 14.7% of PCIs. The use of pressure wires also increased (6.3% vs 2021) as did plaque modification techniques. Primary PCI continued to grow and was the most frequent treatment (97%) in ST-segment elevation myocardial infarction. Most noncoronary procedures maintained their upward trend, particularly percutaneous aortic valve implantation, atrial appendage closure, mitral/tricuspid edge-to-edge therapy, renal denervation, and percutaneous treatment of pulmonary arterial disease. CONCLUSIONS: The Spanish cardiac catheterization and coronary intervention registry for 2022 reveals a rise in the complexity of coronary disease, along with a notable growth in procedures for valvular and nonvalvular structural heart disease.
Subject(s)
Cardiology , Coronary Artery Disease , Percutaneous Coronary Intervention , Humans , Cardiac Catheterization , RegistriesABSTRACT
No disponible
Subject(s)
Humans , Female , Aged, 80 and over , Blood Vessel Prosthesis , Varicose Ulcer/surgery , Aortic Diseases/surgery , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Amyloid Neuropathies, Familial/genetics , Prealbumin/metabolism , Heart Diseases/genetics , Electrocardiography/methods , Mutation/genetics , Homozygote , Biopsy/methods , Pulmonary Edema/diagnostic imaging , Biomarkers/analysisSubject(s)
Amyloid Neuropathies, Familial/genetics , Cardiomyopathies/genetics , DNA/genetics , Mutation , Prealbumin/genetics , White People , Amyloid Neuropathies, Familial/diagnosis , Amyloid Neuropathies, Familial/metabolism , Biopsy , Cardiomyopathies/diagnosis , Cardiomyopathies/metabolism , DNA Mutational Analysis , Echocardiography , Electrocardiography , Humans , Magnetic Resonance Imaging, Cine , Male , Middle Aged , Pedigree , Prealbumin/metabolismSubject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Cardiology Service, Hospital , Catheterization, Peripheral , Femoral Artery , Hospital Departments , Transcatheter Aortic Valve Replacement , Aged , Aged, 80 and over , Aortic Valve/diagnostic imaging , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/mortality , Catheterization, Peripheral/adverse effects , Catheterization, Peripheral/mortality , Female , Humans , Male , Patient Safety , Postoperative Complications/etiology , Prospective Studies , Punctures , Registries , Risk Assessment , Risk Factors , Spain , Transcatheter Aortic Valve Replacement/adverse effects , Transcatheter Aortic Valve Replacement/mortality , Treatment OutcomeABSTRACT
Ergotamine is used to abort or prevent migraine. The most common adverse reactions are nausea, vomiting, myalgia, diarrhea or mouth dryness, and the contraindications are peripheral vascular disease because of its vasospastic effect, and liver disease because the drug is metabolized in this organ. Its effects on the heart are less frequent and less well known. We report two patients on long-term ergotamine treatment who developed valvular disorders.
Subject(s)
Analgesics, Non-Narcotic/adverse effects , Ergotamine/adverse effects , Heart Valve Diseases/chemically induced , Adult , Female , Humans , Male , Middle AgedABSTRACT
La ergotamina se usa para tratar o prevenir migrañas. Las reacciones adversas más comunes son náuseas, vómitos, mialgias, diarreas o xerostomía; su uso está contraindicado en la enfermedad vascular periférica por la producción de vasoespasmos o en enfermedades hepáticas por su metabolización en esta localización. La afección cardíaca es mucho menos frecuente y conocida. Describimos los casos de 2 pacientes con uso crónico de ergotamina con repercusión valvular cardíaca
Ergotamine is used to abort or prevent migraine. The most common adverse reactions are nausea, vomiting, myalgia, diarrhea or mouth dryness, and the contraindications are peripheral vascular disease because of its vasospastic effect, and liver disease because the drug is metabolized in this organ. Its effects on the heart are less frequent and less well known. We report two patients on long-term ergotamine treatment who developed valvular disorders
